drugset / Trial / NCT01670357

Phase II Study of DA-6034 Eye Drops in Dry Eye Syndrome

NCT01670357

Phase 2 Completed 150 enrolled Dong-A ST Co., Ltd.
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is to determine the efficacy and safety of 3% or 5% DA-6034 eye drops compared with placebo in dry eye syndrome.

Timeline

Start
2012-04
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject RECOFLAVONE Small molecule 3 % Other
Subject RECOFLAVONE Small molecule 5 % Other

Indications